Ken Herrmann

CIK: 0002049757

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)3 (50.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKTS

Aktis Oncology, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

AKTS
Aktis Oncology, Inc.
Jul 20, 2026
Exercise(M)
Direct
3.5K shares at avg. $0.08$280.48
AKTS
Aktis Oncology, Inc.
Jul 20, 2026
Exercise(M)
Direct
1.4K shares at avg. $1.91$3K
AKTS
Aktis Oncology, Inc.
Jul 20, 2026
Sale(S)
Direct
3.5K shares at avg. $24.56$86K
AKTS
Aktis Oncology, Inc.
Jul 20, 2026
Sale(S)
Direct
1.4K shares at avg. $24.56$33K
AKTS
Aktis Oncology, Inc.
Jul 17, 2026
Exercise(M)
Direct
3.1K shares at avg. $0.08$245.2
AKTS
Aktis Oncology, Inc.
Jul 17, 2026
Sale(S)
Direct
3.1K shares at avg. $25.21$77K

		Type	Shares	Price		Ownership
Jul 20, 2026	AKTS Aktis Oncology, Inc.	Exercise(M)	3,506	$0.08	$280	Direct
Jul 20, 2026	AKTS Aktis Oncology, Inc.	Exercise(M)	1,350	$1.91	$2,579	Direct
Jul 20, 2026	AKTS Aktis Oncology, Inc.	Sale(S)	3,506	$24.56	$86,115	Direct
Jul 20, 2026	AKTS Aktis Oncology, Inc.	Sale(S)	1,350	$24.56	$33,159	Direct
Jul 17, 2026	AKTS Aktis Oncology, Inc.	Exercise(M)	3,065	$0.08	$245	Direct
Jul 17, 2026	AKTS Aktis Oncology, Inc.	Sale(S)	3,065	$25.21	$77,259	Direct

1-6 of 6 transactions

About Herrmann Ken

Herrmann Ken (SEC CIK 0002049757) files insider reports with the SEC as Director of Aktis Oncology, Inc. (AKTS).

Signal8 holds 3 ownership filings by Herrmann Ken (1 Form 3, 2 Form 4), filed between Jan 8, 2026 and Jul 21, 2026. Those filings report 6 transactions, from Jul 17, 2026 to Jul 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Herrmann Ken's filings is in BOSTON, MA.

Recent filings by Herrmann Ken

Jul 20, 2026: Option exercises of AKTS shares (2 lines, Form 4, code M).
Jul 20, 2026: Open-market sales of AKTS shares (2 lines, Form 4, code S).
Jul 17, 2026: Option exercise of AKTS shares (Form 4, code M).
Jul 17, 2026: Open-market sale of AKTS shares (Form 4, code S).

Other insiders filing for Aktis Oncology, Inc. (AKTS)

Czibere Akos, Chief Medical Officer
Ron-Bigger Shulamit, Chief Operating Officer
Gormley Glenn, Director
ELI LILLY & Co, 10% Owner
Foley Todd, Director
MPM BIOVENTURES 2018, L.P., 10% Owner

How to read Form 4 transaction codes